JNJ4:01 PMGroundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovationjnj.com
JNJ7:45 AMJohnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheterjnj.com
JNJ4:34 PMJohnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conferencejnj.com
JNJ8:00 AMJohnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCPjnj.com
JNJ8:00 AMJohnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remissionjnj.com
JNJ8:05 AMJohnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's diseasejnj.com
JNJ8:05 AMJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel diseasejnj.com
JNJ7:00 AMJohnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic Systemjnj.com
JNJ8:00 AMCAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysisjnj.com
JNJ8:30 AMJohnson & Johnson ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026jnj.com
JNJ4:33 PMJohnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conferencejnj.com
JNJ8:05 AMFDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophreniajnj.com
JNJ8:03 AMFDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)jnj.com
JNJ8:05 AMIMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)jnj.com
JNJ4:22 PMJohnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conferencejnj.com
JNJ7:45 AMJohnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026jnj.com
JNJ6:21 AMJohnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%jnj.com
JNJ8:00 AMJohnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Visionjnj.com